ARCHIVES

Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase

This article is from The Cancer Letter archive.

Vol. 23 No. 48 | December 19, 1997

Download PDF Visit The Full Archive

Related Articles

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

December 27, 2013

Newest NIH Institute, NIBIB, Gets An Acting Director.

May 11, 2001

Compendium Drops Listing of Aranesp for Anemia of Cancer.

February 23, 2007

Five Years after Proton Therapy, 75-99% of Men Live Cancer-Free

February 28, 2014

“Wild West” of Molecular Testing?: Caris Engaged in Aggressive Marketing, Improper Medicare Billing, Lawsuit Alleges

August 8, 2014

Freestanding Cancer Centers May Be The “Missing Ingredient In Cancer Treatment,” DeVita Believes

January 11, 1985